SOUTH SAN FRANCISCO, Calif., Jan. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 123,000 shares of the Company's common stock to three newly hired employees.

加利福尼亚州南旧金山，2024年1月26日，致力于发现和开发靶向治疗药物的精准医学肿瘤学公司IDEAYA Biosciences，Inc.（纳斯达克：IDIA）今天宣布，2024年1月25日，IDEAYA董事会薪酬委员会授予不合格股票期权，向三名新聘用的员工购买总计123000股公司普通股。

The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)..

股票期权是根据IDEAYA Biosciences，Inc.2023年就业诱导奖励计划（2023年诱导计划）授予的，作为根据纳斯达克上市规则5635（c）（4）的规定，这些个人在IDEAYA就业的诱导材料。。

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4)..

根据纳斯达克上市规则5635（c）（4），2023年激励计划专门用于向以前不是IDEAYA员工的个人或在经过一段真正的非雇佣期后的个人授予股权奖励，作为这些个人在IDEAYA就业的激励材料。。

The stock options have an exercise price of $42.50 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

股票期权的行权价格为每股42.50美元，相当于IDEAYA普通股在授予日在纳斯达克全球精选市场的收盘价。股票期权的期限为10年，将在四年内授予，25%的期权在授予开始日期的第一周年授予，其余75%的期权在此后的三年内按月等额分期授予。

Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date..

股票期权的授予取决于该员工在每个授予日期继续向IDEAYA提供服务。。

About IDEAYA Biosciences

关于IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.

IDEAYA是一家精准医学肿瘤学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向治疗药物。IDEAYA的方法将识别和验证转化生物标志物的能力与药物发现相结合，以选择最有可能从其靶向治疗中受益的患者群体。

IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. .

IDEAYA正在将其早期的研究和药物发现能力应用于合成致死率，这代表了一类新兴的精准医学目标。。

Investor and Media Contact

投资者和媒体联系

IDEAYA Biosciences

Ideaya生物科学

Andres Ruiz Briseno

安德烈斯·鲁伊斯·布里塞诺

Senior Vice President, Head of Finance and Investor Relations

高级副总裁、财务和投资者关系主管

investor@ideayabio.com

investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302045265.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302045265.html

SOURCE IDEAYA Biosciences, Inc.

来源：IDEAYA Biosciences，Inc。

Company Codes: NASDAQ-NMS:IDYA

公司代码：NASDAQ-NMS：IDIA